CSPAN2 Part 1 House Energy Subcommittee Hearing On Prescription Drug Prices July 14, 2024
Her Covert Affairs team have no influence or insight into the resourcing over all. I cant comment that we can get back to you. Thank you for your comments, congressman. So thats exactly why we are here. I speak for a section of the pharmaceutical industry that few people actually appreciate, especially given the statistics that i referenced that two out of every three new drugs approved by the fda last year actually originated in companies that are small biopharmaceutical emerging companies. We dont have a voice in washington. Excelixis is not a member of pharma. Where a number of bio. We dont...
Source: archive.org